ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2008

Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts

Yasuto Araki1, Keita Okamoto 1, Yoshimi Aizaki 1, Hiromi Oda 2 and Toshihide Mimura 1, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cytokines and chemokines, Epigenetics, pathogenesis, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints. The inflammatory process causes the activation of synovial fibroblasts (SFs) and the destruction of articular cartilage and bone, resulting in disability of the joints. Both genetic and environmental factors have been shown to be associated with the pathogenesis of RA. However, these factors are unable to explain the pathogenesis of RA completely. Epigenetic factors such as histone lysine methylation are suggested to be associated with the pathogenesis of RA. Epigenetics refers to heritable phenotypic changes that influence gene expression independently of the DNA sequence. Aberrant gene expression of MLL1, which catalyzes methylation of histone H3 lysine 4 (H3K4), has been reported in RASFs. The aim of this study is to elucidate the involvement of MLL1 in the pathogenesis of RA.

Methods: SFs were isolated from synovial tissues obtained from patients with RA or osteoarthritis (OA) during total knee joint replacement. MLL1 expression in the cultured SFs was evaluated after stimulation with tumor necrosis factor α (TNFα). We examined the changes in the expression of RA-associated genes, including matrix metalloproteinases (MMP-1, MMP-3, MMP-9, and MMP-13), cathepsins (CTSK and CTSL), cytokines (IL-6, IL-8, IL-15, and IL-23A), and chemokines (CCL2, CCL3, CCL5, CXCL1, CXCL5, CXCL6, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, and CX3CL1), as well as the trimethylation of H3K4 (H3K4me3) levels in the promoters upon siRNA-mediated depletion of MLL1 in RASFs. The changes in the gene expression were also investigated by the treatment with an MLL1 inhibitor MM-102. The H3K4me3 levels in the cytokine and chemokine promoters were also examined in RASFs and OASFs.

Results: The levels of MLL1 mRNA and protein were higher after TNFα stimulation in RASFs versus OASFs. The mRNA levels of IL-6, IL-15, CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1 genes were significantly decreased in MLL1 siRNA-treated RASFs. Correspondingly, the H3K4me3 levels in the promoters were significantly repressed. MM-102 significantly decreased CCL5, CXCL9, CXCL10, and CXCL11 mRNA levels in RASFs. MM-102 also repressed the H3K4me3 levels in the promoters in RASFs. In addition, the H3K4me3 levels in the IL-6, IL-15, CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1 promoters were significantly higher in RASFs than OASFs.

Conclusion: Study findings suggest that MLL1 regulates expression of the cytokines and chemokines that are involved in the pathogenesis of RASFs. MLL1 may be a new target for RA therapy.

The silencing of MLL1 significantly decreased the mRNA levels of two cytokines -IL-6, IL-15- and six chemokines -CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1- in RASFs -N=12, *P<0.05, **P<0.01-.

The H3K4me3 levels in two cytokines -IL-6, IL-15- and six chemokines -CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1- genes were significantly decreased in MLL1 siRNA-treated RASFs -N=7, *P<0.05, **P<0.01-.

The H3K4me3 levels in two cytokines -IL-6, IL-15- and six chemokines -CCL2, CCL5, CXCL9, CXCL10, CXCL11, and CX3CL1- promoters were significantly higher in RASFs than OASFs -OA: N=8, RA: N=14, *P<0.05, **P<0.01, ***P<0.001-.


Disclosure: Y. Araki, None; K. Okamoto, None; Y. Aizaki, None; H. Oda, None; T. Mimura, None.

To cite this abstract in AMA style:

Araki Y, Okamoto K, Aizaki Y, Oda H, Mimura T. Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/histone-lysine-methyltransferase-mll1-regulates-the-expression-of-cytokines-and-chemokines-in-rheumatoid-arthritis-synovial-fibroblasts/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histone-lysine-methyltransferase-mll1-regulates-the-expression-of-cytokines-and-chemokines-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology